The European Medicines Agency (EMA) published on 24 April 2026 the minutes of its Committee for Veterinary Medicinal Products (CVMP) meeting held from 10-12 February 2026. The committee adopted positive opinions for two new veterinary vaccines and recommended a class-wide review of certain antiparasitics due to emerging resistance concerns, while also finalizing guidance on environmental risk assessment for veterinary products.
The CVMP, responsible for evaluating veterinary medicines in the EU's centralized authorization procedure, granted positive opinions for two new vaccines targeting livestock diseases, expanding treatment options for animal health professionals and livestock producers. The committee also recommended a class-wide review of antiparasitic drugs, signaling growing regulatory attention to resistance issues that could impact the efficacy of existing treatments.
The finalized guidance on environmental risk assessment aims to standardize how veterinary product developers evaluate ecological impacts, potentially increasing compliance costs for pharmaceutical companies but providing clearer pathways for market authorization. The document type is official meeting minutes, which are not legally binding but reflect the committee's scientific recommendations.
Veterinary pharmaceutical companies face potential costs from the antiparasitic review and updated environmental guidance, while animal health professionals and livestock producers may benefit from new vaccines but could face reduced antiparasitic options if resistance concerns lead to restrictions. The EMA's CVMP continues to balance innovation with safety and environmental protection in the veterinary sector.